CSI is now Abbott, and our toolkit for treating vascular diseases just got a little more robust. Abbott on Thursday completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical devices company with innovative technologies for treating complex artery diseases — conditions that impact millions. CSI's focus is systems that treat coronary and peripheral artery disease, which affect an estimated 20 million1 and 8 million2 people in the U.S., respectively. Here are three things to know about the latest addition to Abbott’s Medical Devices business. 1. Why did Abbott acquire CSI? The acquisition is part of an overall investment in our vascular portfolio, which we're expanding to give physicians different options for treating complex artery disease. Offering a variety of ways to clear blood vessels — as well as the imaging and stents needed to do so effectively — helps physicians provide the best care for patients. Abbott acquired peripheral thrombectomy systems company Walk Vascular in 2021.